Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
Summary
The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).
Official title: Expanded Access Treatment Protocol for Bulevirtide
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-06-12
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
Bulevirtide
10 mg BLV will be administered via subcutaneous injection